Trial Profile
Phase II, Single-arm Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 07 Jun 2021 Status changed from active, no longer recruiting to completed.
- 17 May 2019 Planned End Date changed from 31 Dec 2018 to 30 Sep 2020.
- 17 May 2019 Planned primary completion date changed from 1 Nov 2018 to 31 Dec 2019.